The in vitro efficacy of EpCAM×CD3 antibody was tested in a FACS-based cytotoxicity assay using CD3-positive pre-activated PBMCs of healthy donors as effector cells and EpCAM-positive human RB cells as target cells (tumor 1). This evidence concerns the gene EPCAM and neoplasm.